- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Genome Sequencing Services Facility by InterpretOmics to start in Banglore
Banglore :Genomic data science company InterpretOmics on Monday announced opening a next generation facility here to offer genome sequencing services to research and development institutes, pharma units and biotech firms.Set up at a cost of Rs.3.5 crore, the hit-tech facility will also be a biomarker discovery, drug target discovery and trial stratification for biotech, pharma and...
"We will provide genomic selection of specific trains in crop development for bio-agriculture firms," InterpretOmics, a research company dedicated to the discovery of novel and innovative approaches to the treatment of complex diseases, said in a statement here.
"The newly inaugurated centre will cater to our growing customer base in next generation sequencing and analysis. The facility also houses a bio-bank," said its co-founder and CEO Prahalad Achutharao.
"The focus is on research, development and delivering model (RDD). Our USP is carrying out R&D along with the delivery. InterpretOmics now has 35 professionals and plans to achieve a head count of 40 by the end of July," he added.
InterpretOmics also provides on-premise and SaaS enterprise-grade software platform for research organisations, pharmaceuticals, biotechnology firms and hospitals to analyse genetic information and identify biomarkers critical to the development of targeted drugs and therapies, the company said in the statement.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751